Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma
- 209 Downloads
Prostate cancer (PCa) has become a prevalent malignant disease in males globally. Accumulating data suggested that hsa-microRNAs (miRNAs) could be potential biomarkers for tumor diagnosis due to their important roles in the cell cycle. This study investigated the diagnostic and prognostic values of hsa-miR-203 and hsa-miR-30c in PCa tissues. There were 44 pathologically confirmed PCa patients who were enrolled in this study. Tissue samples were collected from both tumor tissues and adjacent normal tissues. RNA was extracted and the expression levels of hsa-miR-203 and hsa-miR-30c in tumor and normal tissues were compared. The receiver operating characteristic (ROC) curves were plotted to evaluate the reliability of hsa-miR-203 and hsa-miR-30c in detecting PCa. All subjects in this study were followed up by 36 months, and the Kaplan-Meier method was conducted to investigate the survival status of PCa patients. The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues (P < 0.001), and the predictive power of the two hsa-miRNAs for PCa prognosis was reliable. Besides that, the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of PCa.
KeywordsProstate cancer MicroRNAs Biological markers Diagnosis Prognosis
This study is supported by the National Science Foundation of China (NSFC 81570053), Shanghai Science and Technology Commission Foundation of Key Medical Research (034119868 and 09411951600), and Research Foundation of Shanghai Municipal Health Bureau (20134034).
Compliance with ethical standards
Conflicts of interest
- 2.Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, Fernandez-Serra A, Rubio L, Ramirez-Backhaus M, Arminan A, Dominguez-Escrig J, Martinez F, Garcia-Casado Z, Scotlandi K, Vicent MJ, Lopez-Guerrero JA. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014Google Scholar
- 7.Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999;54:220–4.CrossRefPubMedGoogle Scholar
- 12.Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9:39–45.CrossRefPubMedGoogle Scholar
- 33.Noguchi S, Kumazaki M, Mori T, Baba K, Okuda M, Mizuno T, Akao Y. Analysis of microrna-203 function in CREB/MITF/RAB27a pathway: comparison between canine and human melanoma cells. Vet Comp Oncol 2014Google Scholar
- 43.Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu L, Chen X, Li J, Bai Y. MiR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. J Cell Physiol 2014Google Scholar